Binswanger’s Disease Treatment Market Size, Trends, Scope, Competitive Landscape and Forecast by 2030 - TMR

Binswanger’s Disease: Introduction

Binswanger disease is a progressive neurological disorder caused due to slow or obstructive supply of blood to the deep structures of the brain. The disease is caused by arteriosclerosis, thromboembolism, and other diseases that affect the blood vessels that supply oxygen and nutrients to the white-matter and basal ganglia and thalamus in the brain.
Some of the most common signs and symptoms of Binswanger’s disease are memory loss, depression, inactiveness, apathy, and inability to act or make decisions (abulic). The patient progressively becomes socially withdrawn and exhibit poor judgement with reduced organizational skills. Moreover, the patient experiences difficulty with speech, swallowing (dysphagia), and urinary incontinence. Some patients also exhibit symptoms similar to other neurodegenerative diseases, for instance, symptoms of Parkinson’s such as slowness and poor balance.
Several Binswanger’s disease patients have a history of strokes or transient ischemic attacks. Therefore, the signs and symptoms of this disease develop in a stepwise fashion; in contrast to the insidious, gradually progressive course of neurodegenerative diseases.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure of Binswanger’s Disease Treatment Market Report

Key Drivers and Restraints of Global Binswanger’s Disease Treatment Market

Binswanger’s disease is an age-progressive disease that occurs in individuals aged 50 years or older. Rise in global geriatric population is estimated to fuel the Binswanger’s disease treatment market at a steep pace during the forecast period.
The geriatric population is increasing rapidly. According to the WHO, the global geriatric population is expected to increase from 524 million in 2010 to 1.5 billion by 2050. Aging increases the need for health care, as it renders people prone to cardiovascular diseases, such as coronary heart disease; respiratory diseases, such as TB and pneumonia; dental caries and oral cancer; and orthopedic conditions such as osteoporosis.
Most developed countries have high geriatric population. According to the WHO, the geriatric population is expected to rise at a rapid pace in developed countries such as the U.S., the U.K., and Japan.
Access to various diagnostic and treatment services has improved due to favorable health care policies and the advancement in health care facilities in countries such as the U.S., Japan, the U.K., and other countries in Western Europe, which, in turn, has increased life expectancy of the population. Increase in geriatric population is anticipated to propel the Binswanger’s disease treatment market during the forecast period.
However, lack of disease awareness leading to slow or late diagnosis of patients in developing and under-developed countries is anticipated to hamper the market growth during the forecast period

Surgery to Lead Global Market

The global Binswanger’s disease treatment market can be segmented based on treatment type, end-user, and region
On the basis of treatment type, the market can be segmented into anti-hypertensive drugs, statins, anti-platelet drugs, anti-depressants, and others
Based on distribution channel, the global Binswanger’s disease treatment market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies

Stuck in a Neck-to-Neck Competition with Other Brands? Request a Custom Report on “Binswanger’s Disease Treatment Market” here